Elizabeth A Swallow1, Mohammad W Aref1, Corinne E Metzger1, Spencer Sacks2, Demi R Lehmkuhler1, Neal Chen2, Max A Hammond1, Paul R Territo3, Thomas L Nickolas4, Sharon M Moe5, Matthew R Allen6. 1. Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, United States. 2. Department of Medicine - Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, United States. 3. Department of Radiology, Indiana University School of Medicine, Indianapolis, IN, United States. 4. Department of Medicine, Columbia University Medical Center, New York, NY, United States. 5. Department of Medicine - Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, United States; Roudebush Veterans Administration Medical Center, Indianapolis, IN, United States. 6. Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, United States; Department of Medicine - Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, United States; Department of Biomedical Engineering, Indiana University Purdue University of Indianapolis, Indianapolis, IN, United States; Roudebush Veterans Administration Medical Center, Indianapolis, IN, United States. Electronic address: matallen@iu.edu.
Abstract
BACKGROUND: Chronic kidney disease (CKD) results in a dramatic increase in skeletal fracture risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but they are not recommended in advanced CKD. We have recently shown higher acute skeletal accumulation of fluorescently-tagged zoledronate (ZOL) in the setting of CKD but how this accumulation is retained/lost over time is unclear. Furthermore, it is unknown if alternative dosing approaches can modulate accumulation in the setting of CKD. METHODS: To address these two questions normal (NL) and Cy/+ (CKD) rats were divided into control groups (no dosing), a single dose of a fluorescent-tagged ZOL (FAM-ZOL), a single dose of non-labelled zoledronate (ZOL) or ten weekly doses of FAM-ZOL each at 1/10th the dose of the single dose group. Half of the CKD animals in each group were provided water with 3% calcium in drinking water (CKD + Ca) to suppress PTH and remodeling. At 30 or 35 weeks of age, serum, tibia, ulna, radius, vertebra, femora, and mandible were collected and subjected to assessment methods including biochemistry, dynamic histomorphometry and multi-spectral fluorescence levels (using IVIS SpectrumCT). RESULTS: FAM-ZOL did not significantly reduce bone remodeling in either NL or CKD animals while Ca supplementation in CKD produced remodeling levels comparable to NL. At five- and ten-weeks post-dosing, both CKD and CKD + Ca groups had higher levels of FAM-ZOL in most, but not all, skeletal sites compared to NL with no difference between the two CKD groups suggesting that the rate of remodeling did not affect skeletal retention of FAM-ZOL. Fractionating the FAM-ZOL into ten weekly doses led to 20-32% less (p < 0.05) accumulation/retention of compound in the vertebra, radius, and ulna compared to administration as a single dose. CONCLUSIONS: The rate of bone turnover does not have significant effects on levels of FAM-ZOL accumulation/retention in animals with CKD. A lower dose/more frequent administration paradigm results in lower levels of accumulation/retention over time. These data provide information that could better inform the use of bisphosphonates in the setting of CKD in order to combat the dramatic increase in fracture risk.
BACKGROUND:Chronic kidney disease (CKD) results in a dramatic increase in skeletal fracture risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but they are not recommended in advanced CKD. We have recently shown higher acute skeletal accumulation of fluorescently-tagged zoledronate (ZOL) in the setting of CKD but how this accumulation is retained/lost over time is unclear. Furthermore, it is unknown if alternative dosing approaches can modulate accumulation in the setting of CKD. METHODS: To address these two questions normal (NL) and Cy/+ (CKD) rats were divided into control groups (no dosing), a single dose of a fluorescent-tagged ZOL (FAM-ZOL), a single dose of non-labelled zoledronate (ZOL) or ten weekly doses of FAM-ZOL each at 1/10th the dose of the single dose group. Half of the CKD animals in each group were provided water with 3% calcium in drinking water (CKD + Ca) to suppress PTH and remodeling. At 30 or 35 weeks of age, serum, tibia, ulna, radius, vertebra, femora, and mandible were collected and subjected to assessment methods including biochemistry, dynamic histomorphometry and multi-spectral fluorescence levels (using IVIS SpectrumCT). RESULTS:FAM-ZOL did not significantly reduce bone remodeling in either NL or CKD animals while Ca supplementation in CKD produced remodeling levels comparable to NL. At five- and ten-weeks post-dosing, both CKD and CKD + Ca groups had higher levels of FAM-ZOL in most, but not all, skeletal sites compared to NL with no difference between the two CKD groups suggesting that the rate of remodeling did not affect skeletal retention of FAM-ZOL. Fractionating the FAM-ZOL into ten weekly doses led to 20-32% less (p < 0.05) accumulation/retention of compound in the vertebra, radius, and ulna compared to administration as a single dose. CONCLUSIONS: The rate of bone turnover does not have significant effects on levels of FAM-ZOL accumulation/retention in animals with CKD. A lower dose/more frequent administration paradigm results in lower levels of accumulation/retention over time. These data provide information that could better inform the use of bisphosphonates in the setting of CKD in order to combat the dramatic increase in fracture risk.
Authors: Christoph Pautke; Stephan Vogt; Thomas Tischer; Gabriele Wexel; Herbert Deppe; Stefan Milz; Matthias Schieker; Andreas Kolk Journal: Bone Date: 2005-10 Impact factor: 4.398
Authors: Sharon M Moe; Neal X Chen; Mark F Seifert; Rachel M Sinders; Dana Duan; Xianming Chen; Yun Liang; J Scott Radcliff; Kenneth E White; Vincent H Gattone Journal: Kidney Int Date: 2008-09-17 Impact factor: 10.612
Authors: S Moe; T Drüeke; J Cunningham; W Goodman; K Martin; K Olgaard; S Ott; S Sprague; N Lameire; G Eknoyan Journal: Kidney Int Date: 2006-06 Impact factor: 10.612
Authors: Kenneth M Kozloff; Luisa Quinti; Somying Patntirapong; Peter V Hauschka; Ching-Hsuan Tung; Ralph Weissleder; Umar Mahmood Journal: Bone Date: 2008-10-22 Impact factor: 4.398
Authors: R K Fuchs; M R Allen; K W Condon; S Reinwald; L M Miller; D McClenathan; B Keck; R J Phipps; D B Burr Journal: Osteoporos Int Date: 2008-04-03 Impact factor: 5.071
Authors: Elizabeth A Swallow; Corinne E Metzger; Neal X Chen; Joseph M Wallace; Samantha P Tippen; Rachel Kohler; Sharon M Moe; Matthew R Allen Journal: Bone Rep Date: 2022-02-07